B-Cell Chronic Lymphocytic Leukemia – Pipeline Review, H1 2018

Global Markets Direct’s, ‘B-Cell Chronic Lymphocytic Leukemia – Pipeline Review, H1 2018’, provides an overview of the B-Cell Chronic Lymphocytic Leukemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for B-Cell Chronic Lymphocytic Leukemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for B-Cell Chronic Lymphocytic Leukemia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of B-Cell Chronic Lymphocytic Leukemia

– The report reviews pipeline therapeutics for B-Cell Chronic Lymphocytic Leukemia by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved B-Cell Chronic Lymphocytic Leukemia therapeutics and enlists all their major and minor projects

– The report assesses B-Cell Chronic Lymphocytic Leukemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for B-Cell Chronic Lymphocytic Leukemia

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for B-Cell Chronic Lymphocytic Leukemia

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding B-Cell Chronic Lymphocytic Leukemia pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AB Science SA

Aduro BioTech Inc

AstraZeneca Plc

Bayer AG

BioInvent International AB

Celgene Corp

Cell Source Inc

Cellectis SA

Chugai Pharmaceutical Co Ltd

Dynavax Technologies Corp

Elsalys Biotech SAS

iDD biotech SAS

Immunomedics Inc

Juno Therapeutics Inc

Lymphocyte Activation Technologies SA

MEI Pharma Inc

Millennium Pharmaceuticals Inc

Molecular Templates Inc

Novartis AG

Noxxon Pharma AG

Ono Pharmaceutical Co Ltd

Portola Pharmaceuticals Inc

Regeneron Pharmaceuticals Inc

Samumed LLC

Sunesis Pharmaceuticals Inc

TheraMAB LLC

Unum Therapeutics Inc

Xencor Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

B-Cell Chronic Lymphocytic Leukemia Overview 8

B-Cell Chronic Lymphocytic Leukemia Therapeutics Development 9

Pipeline Overview 9

Pipeline by Companies 10

Pipeline by Universities/Institutes 13

Products under Development by Companies 14

Products under Development by Universities/Institutes 16

B-Cell Chronic Lymphocytic Leukemia Therapeutics Assessment 17

Assessment by Target 17

Assessment by Mechanism of Action 20

Assessment by Route of Administration 23

Assessment by Molecule Type 25

B-Cell Chronic Lymphocytic Leukemia Companies Involved in Therapeutics Development 27

AB Science SA 27

Aduro BioTech Inc 27

AstraZeneca Plc 28

Bayer AG 28

BioInvent International AB 29

Celgene Corp 29

Cell Source Inc 30

Cellectis SA 30

Chugai Pharmaceutical Co Ltd 30

Dynavax Technologies Corp 31

Elsalys Biotech SAS 31

iDD biotech SAS 32

Immunomedics Inc 32

Juno Therapeutics Inc 33

Lymphocyte Activation Technologies SA 33

MEI Pharma Inc 33

Millennium Pharmaceuticals Inc 34

Molecular Templates Inc 34

Novartis AG 35

Noxxon Pharma AG 35

Ono Pharmaceutical Co Ltd 35

Portola Pharmaceuticals Inc 36

Regeneron Pharmaceuticals Inc 36

Samumed LLC 37

Sunesis Pharmaceuticals Inc 37

TheraMAB LLC 38

Unum Therapeutics Inc 38

Xencor Inc 39

B-Cell Chronic Lymphocytic Leukemia Drug Profiles 40

202-b Drug Profile 40

2X-121 Drug Profile 42

AB-8779 Drug Profile 45

alemtuzumab biosimilar Drug Profile 46

alisertib Drug Profile 47

Aurixim Drug Profile 53

AZD-4573 Drug Profile 54

BI-1206 Drug Profile 55

BION-1301 Drug Profile 57

Cellular Immunotherapy for Chronic Lymphocytic Leukaemia Drug Profile 59

Cellular Immunotherapy for Hematological Malignancies Drug Profile 60

Cellular Immunotherapy to Activate 4-1BBL and to Target CD19 for B-Cell Malignancies Drug Profile 61

Cellular Immunotherapy to Target CD16 for B-Cell Non-Hodgkin Lymphoma and B-Cell Chronic Lymphocytic Leukemia Drug Profile 64

Cellular Immunotherapy to Target CD19 for B-Cell Chronic Lymphocytic Leukemia Drug Profile 65

Cellular Immunotherapy to Target CD19 for B-Cell Malignancies Drug Profile 66

Cellular Immunotherapy to Target CD19 for Oncology Drug Profile 67

Cellular Immunotherapy to Target CD19 for Oncology Drug Profile 68

Cellular Immunotherapy to Target CD19 for Oncology Drug Profile 69

cerdulatinib Drug Profile 70

copanlisib hydrochloride Drug Profile 75

DTRMWXHS-12 Drug Profile 82

ELB-021 Drug Profile 83

IDD-001 Drug Profile 84

IDD-002 Drug Profile 85

lenalidomide Drug Profile 86

ME-401 Drug Profile 104

mRNA ACTR + rituximab Drug Profile 106

MT-3724 Drug Profile 108

olaptesed pegol Drug Profile 111

REGN-1979 Drug Profile 116

SD-101 Drug Profile 117

SM-08502 Drug Profile 122

TAB-08 Drug Profile 123

tirabrutinib Drug Profile 126

tisagenlecleucel Drug Profile 129

tocilizumab Drug Profile 140

UCART-22 Drug Profile 151

UCARTCS-1 Drug Profile 152

vecabrutinib Drug Profile 153

XmAb-13676 Drug Profile 156

B-Cell Chronic Lymphocytic Leukemia Dormant Projects 158

B-Cell Chronic Lymphocytic Leukemia Discontinued Products 160

B-Cell Chronic Lymphocytic Leukemia Product Development Milestones 161

Featured News & Press Releases 161

Appendix 163

Methodology 163

Coverage 163

Secondary Research 163

Primary Research 163

Expert Panel Validation 163

Contact Us 163

Disclaimer 164

List of Tables

List of Tables

Number of Products under Development for B-Cell Chronic Lymphocytic Leukemia, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Target, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

B-Cell Chronic Lymphocytic Leukemia Pipeline by AB Science SA, H1 2018

B-Cell Chronic Lymphocytic Leukemia Pipeline by Aduro BioTech Inc, H1 2018

B-Cell Chronic Lymphocytic Leukemia Pipeline by AstraZeneca Plc, H1 2018

B-Cell Chronic Lymphocytic Leukemia Pipeline by Bayer AG, H1 2018

B-Cell Chronic Lymphocytic Leukemia Pipeline by BioInvent International AB, H1 2018

B-Cell Chronic Lymphocytic Leukemia Pipeline by Celgene Corp, H1 2018

B-Cell Chronic Lymphocytic Leukemia Pipeline by Cell Source Inc, H1 2018

B-Cell Chronic Lymphocytic Leukemia Pipeline by Cellectis SA, H1 2018

B-Cell Chronic Lymphocytic Leukemia Pipeline by Chugai Pharmaceutical Co Ltd, H1 2018

B-Cell Chronic Lymphocytic Leukemia Pipeline by Dynavax Technologies Corp, H1 2018

B-Cell Chronic Lymphocytic Leukemia Pipeline by Elsalys Biotech SAS, H1 2018

B-Cell Chronic Lymphocytic Leukemia Pipeline by iDD biotech SAS, H1 2018

B-Cell Chronic Lymphocytic Leukemia Pipeline by Immunomedics Inc, H1 2018

B-Cell Chronic Lymphocytic Leukemia Pipeline by Juno Therapeutics Inc, H1 2018

B-Cell Chronic Lymphocytic Leukemia Pipeline by Lymphocyte Activation Technologies SA, H1 2018

B-Cell Chronic Lymphocytic Leukemia Pipeline by MEI Pharma Inc, H1 2018

B-Cell Chronic Lymphocytic Leukemia Pipeline by Millennium Pharmaceuticals Inc, H1 2018

B-Cell Chronic Lymphocytic Leukemia Pipeline by Molecular Templates Inc, H1 2018

B-Cell Chronic Lymphocytic Leukemia Pipeline by Novartis AG, H1 2018

B-Cell Chronic Lymphocytic Leukemia Pipeline by Noxxon Pharma AG, H1 2018

B-Cell Chronic Lymphocytic Leukemia Pipeline by Ono Pharmaceutical Co Ltd, H1 2018

B-Cell Chronic Lymphocytic Leukemia Pipeline by Portola Pharmaceuticals Inc, H1 2018

B-Cell Chronic Lymphocytic Leukemia Pipeline by Regeneron Pharmaceuticals Inc, H1 2018

B-Cell Chronic Lymphocytic Leukemia Pipeline by Samumed LLC, H1 2018

B-Cell Chronic Lymphocytic Leukemia Pipeline by Sunesis Pharmaceuticals Inc, H1 2018

B-Cell Chronic Lymphocytic Leukemia Pipeline by TheraMAB LLC, H1 2018

B-Cell Chronic Lymphocytic Leukemia Pipeline by Unum Therapeutics Inc, H1 2018

B-Cell Chronic Lymphocytic Leukemia Pipeline by Xencor Inc, H1 2018

B-Cell Chronic Lymphocytic Leukemia Dormant Projects, H1 2018

B-Cell Chronic Lymphocytic Leukemia Dormant Projects, H1 2018 (Contd..1), H1 2018

B-Cell Chronic Lymphocytic Leukemia Discontinued Products, H1 2018

List of Figures

List of Figures

Number of Products under Development for B-Cell Chronic Lymphocytic Leukemia, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports